Farallon Capital Management
http://www.faralloncapital.com/farallon/index.htmFarallon Capital Management is an investment firm than manages equity capital for institutions and high net worth individuals. The firm's institutional investors are primarily college endowments and foundations. Farallon primarily invests in businesses and securities that are undergoing change or will appreciate because of an expected event which includes mergers, restructurings, recapitalizations or other major changes. The firm seeks to build strong relationships with the management of companies in which it invests.
View Older Stories View More Recent Stories
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form SCHEDULE 13G/A Liquidia Corp Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A AGIOS PHARMACEUTICALS, Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Revolution Medicines, Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Beta Bionics, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A GRAIL, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A ASSEMBLY BIOSCIENCES, Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Savara Inc Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G Minerva Neurosciences, Filed by: Farallon Capital Partners, L.P.
-
Freenome to go public via SPAC merger with $240 million funding
-
Form SCHEDULE 13G GRAIL, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form N-PX/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form SCHEDULE 13G GRAIL, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Liquidia Corp Filed by: Farallon Capital Partners, L.P.
-
Tango Therapeutics raises $225 million in stock offering
-
Minerva Neurosciences secures up to $200 million for schizophrenia drug trial
-
GRAIL raises $325 million in private placement financing
-
Form SCHEDULE 13G Crinetics Pharmaceutical Filed by: Farallon Capital Partners, L.P.
-
Form N-PX FARALLON CAPITAL MANAGEM For: Jun 30
-
GoPro registers warrant resale covering 11 million shares
-
Form SCHEDULE 13G ASSEMBLY BIOSCIENCES, Filed by: Farallon Capital Partners, L.P.
-
Form N-PX/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30

